Thursday, 12 March 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 12 March 2026
News

Aussies behind new US pharma

Posted 18 January 2024 PM

An Aussie invention has led to the creation of a new US-based neuroscience company focused on advancing first and best in class drugs for central nervous system related conditions.

In a year end update to investors, Boston-based biotherapeutics company, PureTech Health announced the launch of Seaport Therapeutics, a new clinical-stage company based around a lymphatic-targeting drug delivery platform licensed from Monash University researchers in 2017.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (12)

Clinical & Medical, R&D (3)

Regulatory, Pharmacovigilance & QA (8)

Devices (1)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.